Sanofi sells rare disease med Enjaymo to Recordati for $825M
WEB12 hours ago · Recordati is floating $825 million upfront—plus another $250 million in potential commercial milestones—to get its hands on the global rights to Sanofi’s rare disease biologic Enjaymo.
WEBMilan, 4th October 2024 – Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic which is the only approved targeted product for the treatment of cold agglutinin disease (CAD), …
RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO ...
WEB1 day ago · Milan, 4 th October 2024 – Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic which is the only approved targeted product for ...
Sanofi Sells Global Rights To Rare Autoimmume Drug Enjaymo …
WEB11 hours ago · On Friday, Italian pharma company Recordati S.p.A agreed to acquire the global rights to Enjaymo (sutimlimab) from Sanofi SA (NASDAQ:SNY) for $825 million as an upfront payment and additional ...
Recordati to Buy Global Rights to Sanofi's Enjaymo for $825 Million
WEB19 hours ago · Recordati reached an agreement with French pharmaceutical company Sanofi to acquire the global rights to autoimmune disorder treatment Enjaymo for $825 million. The Italian pharmaceutical company ...
Recordati buys rights to rare immune disorder drug from Sanofi …
WEB20 hours ago · Recordati said it had signed an agreement for the rights to Enjaymo, a biologic which is the only targeted product for the treatment of CAD approved by the U.S. Food and Drug Administration (FDA).
Sanofi Drug for Rare Blood Disease Is Heading to Recordati for …
WEB1 day ago · Recordati is acquiring Sanofi’s Enjaymo, the only approved drug for the rare blood disorder cold agglutinin disease. Achieving sales milestones could bring the deal’s value to more than $1 ...
Sanofi’s rare disease drug finds yet another home
WEB10 hours ago · Having already been on a winding journey, Enjaymo, which Sanofi acquired through a 2018 buyout of Bioverativ, is now headed to Recordati as part of a deal announced Friday.
Recordati to acquire worldwide rights to Sanofi’s antibody Enjaymo
WEB1 day ago · Recordati has reached an agreement with Sanofi for acquiring the worldwide rights to Enjaymo, the only approved treatment specifically targeting cold agglutinin disease (CAD), a rare B-cell lymphoproliferative disorder.
Sanofi Offloads Rare Autoimmune Drug to Recordati in
WEB13 hours ago · Sanofi sold Enjaymo, its humanized monoclonal antibody treatment for the rare autoimmune disorder cold agglutinin disease, to Italy’s Recordati in an agreement potentially worth more than $1 billion. Under the terms of the deal, Milan-based Recordati will pay $825 million upfront and will pledge up to $250 million in sales-based milestones.
- Some results have been removed